Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
|SUCCES DE LA PREMIERE OPERATION DE RECONSTRUCTION MAMMAIRE AVEC MATTISSE 🚀|
Le 12 juillet 2022, une première patiente atteinte d’un cancer du sein a pu bénéficier d’une reconstruction mammaire grâce à notre implant #MATTISSE.
Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.
Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.
Bordeaux, France, September 5, 2022 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification. This certifies the compliance of FineHeart’s quality management system with medical device industry regulations and has been issued following an audit by BSI, the independent, internationally recognized, accreditation organization.
Digital neuro-rehabilitation platform Neurofenix, which is helping to revolutionise remote rehabilitation for stroke patients, has secured $7million to help fuel its expansion and fund clinical trials in the United States.
|SUCCES DE LA PREMIERE OPERATION DE RECONSTRUCTION MAMMAIRE AVEC MATTISSE 🚀|
Le 12 juillet 2022, une première patiente atteinte d’un cancer du sein a pu bénéficier d’une reconstruction mammaire grâce à notre implant #MATTISSE.
Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
Launch of Vik Atopic Dermatitis in Arabic
After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.
Latest Insights
A wonderful evening with our start-ups, partners, mentors, investors, friends from the Neighborhood community.
Sélectionnées en amont, sept start-ups ont participé au concours de pitchs du septième sommet des start-up et de l’innovation organisé par Challenges ce mercredi 23 mars. Portrait des 7 lauréats.
Paris, October 30, 2021 – Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY” for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.
A wonderful evening with our start-ups, partners, mentors, investors, friends from the Neighborhood community.
Overall demand totaling €14.7 million, 1.24 times the offering The funds raised will be used to implement the strategy of